← Leaderboards
Katherine M Bricker
Emory University
$91,556
Attributed
$91,556
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46K · FY2020–21$50K$37.5K$25K$12.5K$0
'20
'21
Funding mix
By agency
NIH$91,556 · 1
By mechanism
F31$91,556 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Ann M Chahroudi$35,857,595
- Francois J Villinger$61,853,654
- Octavio Ramilo$12,889,369
- Guido Silvestri$61,186,493
- Rama Rao Amara$90,840,294
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultAnimal ModelAntiretroviral TherapyAntiviral TherapyBaseBirthCd4 Positive T LymphocytesCell PhysiologyCellsChildChildhoodClinical TrialsControlled StudyCytokineDesignDigestionDisease OutcomeDisease ProgressionDisease RemissionDysbiosisFaceFunctional DisorderFunding3 Year Old
Grant awards (2)
IL-21 as a Therapeutic to Reduce Immune Activation and Normalize Microbial Dysbiosis in SIV-Infected ART-Suppressed Infant Macaques$46,036
F31 · FY2021 · HD · contact PI
IL-21 as a Therapeutic to Reduce Immune Activation and Normalize Microbial Dysbiosis in SIV-Infected ART-Suppressed Infant Macaques$45,520
F31 · FY2020 · HD · contact PI